Compare Li Auto Inc (LI) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Li Auto Inc vs Eli Lilly And Co — how do they compare? Li Auto Inc trades at $11.54 (market cap $10.71B), while Eli Lilly And Co trades at $1,179.27 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 97.1× Li Auto Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while Li Auto Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Li Auto Inc for 101 Days and Eli Lilly And Co for 93 Days on average.
| LI | LLY | |
|---|---|---|
Market Cap | $10.71B | $1.04T |
Volume | 1,781,143 | 3,064,878 |
Sector | Consumer Cyclical | Health |
52-Week High | $23.13 | $1.28K |
52-Week Low | $10.69 | $799.57 |
Typical Hold Time | 101 Days | 93 Days |
Enterprise Value | $139.58M | $1.09T |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Li Auto (LI) trades at $10.90, down 0.82% and near 52-week lows, reflecting bearish technical signals and recent earnings misses. The company reported declining revenue ($112.31B in 2025) and negative net income margins (-4.4%), though valuation metrics like P/S (0.73) appear attractive. Recent news highlights delivery moderation and new model launches (Li i9, Li MEGA) amid intense EV competition.
The stock faces near-term headwinds from cash burn and competitive pressures, but analyst consensus remains cautiously optimistic with a $15.18 price target. Key risks include execution challenges in global expansion and margin recovery, while potential upside hinges on successful product cycles and cost management improvements.
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company's weight-loss drug portfolio continues to drive exceptional performance, with Q2 2026 EPS of $8.38 beating expectations by 31%. Technical indicators show bullish moving averages while fundamentals reveal impressive 83.4% gross margins and 102.44% ROE. Recent clinical trial successes for next-generation obesity treatments position Lilly for continued market leadership.
LLY presents a compelling growth story with dominant positioning in the expanding obesity/diabetes market, though elevated valuations (P/E 39.26) and regulatory risks require monitoring. Analyst consensus remains strongly bullish with $1,350 price target representing 15% upside. The primary investment thesis centers on pipeline execution and market expansion opportunities, balanced against competitive pressures and valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
